In this segment, Dr. Peter Voorhees presents a modified case involving a patient in their early 70s with relapsed multiple ...

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple ...

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss how treatment selection can be individualized for patients with newly diagnosed multiple myeloma, including considerations when ...

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the biological rationale for targeting ...

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss the design and clinical implications of the CEPHEUS trial in newly diagnosed multiple myeloma, with particular attention to patients ...

The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...

Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted ...

Investigators stated that the results support the proposed mechanism that both retained HER2 expression and elevated CD47 levels may drive efficacy through enhanced antibody-dependent cellular ...

In an interview live from the 2026 International Myeloma Society (IMS) Annual Meeting, Sagar Lonial, MD, discussed the FDA approval of iberdomide, for which data were presented at the meeting, and the ...

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...